The present disclosure relates to hollow fiber tangential flow filters, including hollow fiber tangential flow depth filters, for various applications, including bioprocessing and pharmaceutical applications, systems employing such filters, and methods of filtration using the same.

A filter unit (20, 320, 420, 820, 1020) is provided that includes a filtration chamber (30, 330, 430, 830, 1030) and a filter assembly (32, 132, 232, 432, 532, 632, 732, 832, 1032). A filter cartridge (28, 128, 328, 428, 528, 728, 828, 1028) of the filter assembly (32, 132, 232, 432, 532, 632, 732, 832, 1032) includes a support shell (44, 144, 344, 444, 744, 844) and a filter (60, 860) coupled to a support-shell side wall (50, 350, 850) so as to cover support-shell side openings (52, 352, 852). A handle (62, 162, 262, 362, 662, 762, 862, 1062) of the filter assembly (32, 132, 232, 432, 532, 632, 732, 832, 1032) is coupled to a proximal end of the support shell (44, 144, 344, 444, 744, 844). The filter assembly (32, 132, 232, 432, 532, 632, 732, 832, 1032) is partially insertable into the filtration chamber (30, 330, 430, 830, 1030), such that the filter assembly (32, 132, 232, 432, 532, 632, 732, 832, 1032) passes through a filter-assembly opening (40, 840) of the filtration chamber (30, 330, 430, 830, 1030); the handle (62, 162, 262, 362, 662, 762, 862, 1062) is disposed outside the filtration chamber (30, 330, 430, 830, 1030); and the filter cartridge (28, 128, 328, 428, 528, 728, 828, 1028) is disposed within the filtration chamber (30, 330, 430, 830, 1030). The filter (60, 860) is configured to filter biological particulate from a liquid specimen sample (22) when the liquid specimen sample (22) is driven along a fluid flow path (68, 868) while the filter cartridge (28, 128, 328, 428, 528, 728, 828, 1028) is disposed within the filtration chamber (30, 330, 430, 830, 1030). Other embodiments are also described.

A mixed gas separation method includes a step of supplying a mixed gas to the separation membrane and causing a gas with high permeability in the mixed gas to permeate through the separation membrane. In the step, when ?P is a difference between a gas pressure on the primary side of the separation membrane, i.e., a feed pressure, and a gas pressure on the secondary side of the separation membrane, i.e., a permeate pressure, and A is a Joule-Thomson coefficient, a difference ?T between a gas temperature on the primary side of the separation membrane, i.e., a feed temperature, and a gas temperature on the secondary side of the separation membrane, i.e., a permeate temperature, is made less than 90% of A.Math.?P by setting the Nu number in the mixed gas to be greater than or equal to 2 and less than or equal to 10.

A cross-flow membrane filtration channel defined by at least one membrane, wherein at least one surface of the channel is inclined at an angle away from a centreline of the channel in a direction of feed flow in the channel.

The present disclosure relates to hollow fiber tangential flow filters, including hollow fiber tangential flow depth filters, for various applications, including bioprocessing and pharmaceutical applications, systems employing such filters, and methods of filtration using the same.

Provided in one embodiment is filtering article, comprising: powders comprising bundles of nanotubes, each bundle comprising hollow titania nanotubes. Embodiments of the methods of making and using the filtering articles are also provided.

The invention pertains to a polyaryl ether sulfone polymer solution [solution (SP)] comprising: at least one sulfone polymer [polymer (PSI)] having recurring units, wherein more than 50% moles, with respect to all the recurring units of polymer (PSI), are recurring units (R.sub.PSI) selected from the group consisting of those of formulae (R.sub.PSI-1) and (R.sub.PSI-2) herein below: (R.sub.PSI-1) (R.sub.PSI-2) wherein: each of E, equal to or different from each other and at each occurrence, is selected from the group consisting of those of formulae (E-1) to (E-3): (E-I) (E-II) (E-III) each R is independently selected from the group consisting of halogen, alkyl, alkenyl, alkynyl, aryl, ether, thioether, carboxylic acid, ester, amide, imide, alkali or alkaline earth metal sulfonate, alkyl sulfonate, alkali or alkaline earth metal phosphonate, alkyl phosphonate, amine and quaternary ammonium; and j is zero or an integer of 1 to 4; is a bond or a divalent group optionally comprising one or more than one heteroatom; preferably T is selected from the group consisting of a bond, CH.sub.2, C(O), C(CH.sub.3).sub.2, C(CF.sub.3).sub.2, C(?CCI.sub.2), C(CH.sub.3)(CH.sub.2CH.sub.2COOH), and a group of formula: (A) at least one polar organic solvent [solvent (S)]; and at least one mixture of polyhydroxyl aliphatic alcohols having from 1 to 6 carbon atoms or derivatives thereof [mixture (PHA)], said mixture (PHA) comprising at least one ethylene glycol compound [compound (EthyGly)] and at least one glycerol compound [compound (Gly)], to its use for manufacturing membranes, and to membranes obtained therefrom.

##STR00001##

A detoxification method for treating sepsis, microbial infections, and other inflammatory conditions includes the steps of inducing flow of patient blood through a blood treatment device consisting of a bioreactor inlet and outlet in fluid connection to the circulatory system of a patient. Biological agents including lipopolysaccharide (LPS) and extracellular adenosine triphosphate (ATP) contained within patient blood can be irreversibly detoxified by passage of patient blood over a bioreactor surface having attached or immobilized alkaline phosphatase enzymes and acyloxyacyl hydrolase enzyme, with the bioreactor being contained within the blood treatment device. The method uses continuous treatment of a patient's blood to convert LPS and extracellular ATP in blood into inhibitors of inflammation in vivo without adding any chemicals to the bloodstream of the patient.

A blood treatment method includes the steps of inducing flow of a patient's blood through a blood treatment device inlet and outlet in fluid connection to the circulatory system of the patient. Metastatic deoxyribonucleic acid (DNA) contained within patient blood is destroyed by passing a patient's blood over a bioreactor surface having attached or immobilized deoxyribonuclease 1 (DNase 1) enzyme. The blood treatment device which consists of a bioreactor containing immobilized DNase 1, enables continuous treatment of a patient's blood and increases the effective concentration of DNase 1 in a patient's bloodstream to convert metastasizing cancer DNA in blood into non-oncogenic nucleotide fragments in vivo without adding any chemicals to the blood of the patient.

Provided in one embodiment is a filtering article, comprising: powders comprising bundles of nanotubes, each bundle comprising hollow titania nanotubes. Embodiments of the methods of making and using the filtering articles are also provided.